Employees Retirement System of Texas Lowers Stock Position in Eli Lilly and Company $LLY

Employees Retirement System of Texas trimmed its holdings in Eli Lilly and Company (NYSE:LLY) by 7.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 185,300 shares of the company’s stock after selling 16,000 shares during the quarter. Eli Lilly and Company makes up about 1.1% of Employees Retirement System of Texas’ holdings, making the stock its 14th biggest position. Employees Retirement System of Texas’ holdings in Eli Lilly and Company were worth $141,384,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Brighton Jones LLC increased its stake in Eli Lilly and Company by 22.0% in the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after purchasing an additional 1,730 shares during the period. Revolve Wealth Partners LLC grew its holdings in shares of Eli Lilly and Company by 2.8% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after buying an additional 40 shares during the last quarter. Sequoia Financial Advisors LLC increased its position in Eli Lilly and Company by 19.0% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 140,201 shares of the company’s stock valued at $109,291,000 after acquiring an additional 22,410 shares during the period. Schnieders Capital Management LLC. increased its position in Eli Lilly and Company by 16.7% in the 2nd quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock valued at $6,231,000 after acquiring an additional 1,141 shares during the period. Finally, Jupiter Asset Management Ltd. raised its stake in Eli Lilly and Company by 1.9% during the 2nd quarter. Jupiter Asset Management Ltd. now owns 21,449 shares of the company’s stock valued at $16,720,000 after acquiring an additional 390 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 2.2%

Shares of LLY stock opened at $977.47 on Friday. The business’s fifty day moving average price is $1,039.17 and its 200 day moving average price is $947.29. The firm has a market capitalization of $923.54 billion, a PE ratio of 42.59, a P/E/G ratio of 1.16 and a beta of 0.40. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. The company had revenue of $19.29 billion during the quarter, compared to the consensus estimate of $17.85 billion. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.Eli Lilly and Company’s quarterly revenue was up 42.6% compared to the same quarter last year. During the same quarter last year, the company earned $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, sell-side analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Medicare access is expanding for Zepbound and Mounjaro, which should boost near‑term demand and reduce payer uncertainty for a large patient cohort. Eli Lilly (LLY) and CMS Expand Medicare Access to Zepbound and Mounjaro
• Positive Sentiment: Lilly announced a multibillion manufacturing build‑out in China to secure supply and capture a huge GLP‑1 market — a strategic long‑term revenue driver. Lilly to Invest $3 Billion in China to Boost Obesity Pill
• Positive Sentiment: Lilly is expanding manufacturing and partnerships in Asia (Korea $500M incubator and Japan plant expansion), diversifying capacity and helping global rollout. Eli Lilly invests $500 million in Korea’s biotech growth
• Positive Sentiment: Lilly is pushing multiple product catalysts: an orforglipron filing/launch (oral GLP‑1) and follow‑on candidates (retatrutide) that can sustain growth beyond current injectables. Will Policy Shifts Accelerate Demand for Eli Lilly’s GLP‑1 Drugs?
• Positive Sentiment: Employer Connect and LillyDirect initiatives aim to expand coverage and patient access (potential volume growth even if pricing is pressured). Lilly Employer Connect platform launch
• Neutral Sentiment: Premium share price and 5‑year outperformance have reignited stock‑split and megatrend commentary — sentiment boosters but not immediate fundamentals. Megatrends Still Matter: 3 Growth Stocks for the Next 10 Years (LLY)
• Negative Sentiment: Lilly issued warnings after detecting an unknown impurity in compounded tirzepatide mixed with vitamin B12 — a safety/regulatory concern that can drive near‑term caution and compounding‑market scrutiny. Using Obesity Drug? Eli Lilly Flags Unknown Impurity Found In Compounded Weight Loss Drugs With Vitamin B12
• Negative Sentiment: Shorter‑term technical/market‑sentiment concerns: some analysts/public pieces argue trading momentum has cooled since late 2025, which can accelerate sell‑offs after recent gains. Eli Lilly Reaching For Peak GLP‑1 Euphoria: Rotten Trading Momentum Since November
• Negative Sentiment: Lilly warned some Medicare plans or basic Part D designs might still leave patients with >$50 out‑of‑pocket costs under new CMS rules — a potential near‑term headwind to access and PR. Lilly Warns Some Medicare GLP‑1 Costs Could Exceed $50

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. Barclays assumed coverage on Eli Lilly and Company in a research note on Thursday, February 19th. They issued an “overweight” rating and a $1,350.00 target price on the stock. Berenberg Bank increased their price target on Eli Lilly and Company from $950.00 to $1,050.00 and gave the stock a “hold” rating in a report on Thursday, February 19th. National Bank Financial set a $1,286.00 price objective on shares of Eli Lilly and Company in a research report on Monday, December 1st. Bank of America dropped their price objective on shares of Eli Lilly and Company from $1,286.00 to $1,268.00 and set a “buy” rating on the stock in a research note on Monday, December 15th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $1,285.00 target price on shares of Eli Lilly and Company in a research note on Friday, March 6th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $1,229.59.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.